This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2005 through 2015. The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen, Inc., Takeda Pharmaceutical Company Limited, and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS

ANTI-OBESITY DRUGS
A GLOBAL STRATEGIC BUSINESS REPORT    MCP-1722


                                         CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope of Study                            I-3


 II. EXECUTIVE SUMMARY

  1. Industry Overview                                                  II-1
      Current & Future Analysis                                         II-1
      Factors Influencing the Market                                    II-1
      Obesity - A Global Epidemic                                       II-1
       Table 1: Global Overweight Prevalence (2006): Overweight
       Population (%) of Select Countries (includes corresponding
       Graph/Chart)                                                     II-3

       Table 2: Abdominal Obesity Prevalence (%) by Region and Sex
       (includes corresponding Graph/Chart)                             II-3
      Trends and Issues                                                 II-4
       Obesity: An Unmet Medical Need                                   II-4
       Rising Demand for Obesity Therapeutics                           II-4
       Barriers to Development of Effective Drugs                       II-4
       New Research Aids in Discovery of Novel Drugs                    II-5
       Growing Problem of Obesity in Asia Particularly China            II-5

  2. Competition                                                        II-6
      Roche Leads the Race                                              II-6
       Table 3: Leading Brands in the Global Anti-obesity Drugs
       Market (2007): Percentage Share Breakdown of Revenues for
       Xenical/orlistat, Reductil/Meridia (sibutramine), Alli,
       Acomplia and Others (includes corresponding Graph/Chart)         II-6
      Competition Grows with Pipeline Drugs                             II-7
       Current Anti-Obesity Drugs in Pipeline: 2008                     II-7

  3. Obesity - An Introduction                                          II-8
      Diagnosis of Obesity                                              II-8
       BMI Calculation and Classification                               II-8
       Waist Circumference and BMI                                      II-9
      Causes of Obesity                                                 II-9
       Unhealthy Eating Habits                                          II-9
       Environmental and Genetic Factors                                II-9
       Sedentary Lifestyle                                              II-9
       Alcohol Intake                                                   II-9
       Childhood Obesity                                                II-10
       Psychological Factors                                            II-10
       Pregnancy                                                        II-10
       Hormonal Disorders                                               II-10
       Drugs                                                            II-10
       Aging                                                            II-10
      Risks Associated with Obesity                                     II-10

  4. Obesity Treatment                                                  II-12
      Dietary Therapy                                                   II-12
      Exercise Therapy                                                  II-12
      Behavior Therapy                                                  II-12
      Pharmacotherapy                                                   II-12
      Weight Loss Surgery                                               II-12
      Invasive Vis-à-vis Non-invasive Procedures                        II-12
       A Brief Review of Select Invasive Procedures                     II-13
        Bariatric Surgery                                               II-13
        Laparoscopic Adjustable Gastric Banding                         II-13
        Vertical Banded Gastroplasty (VBG)                              II-13
        Roux-en-Y Gastric Bypass Procedure (RYGB)                       II-13
        Lap-Band Procedure                                              II-13
        Gastric Band Procedure                                          II-13
        Gastric Bypass Procedure                                        II-13
        Doudenal Switch                                                 II-13
      Prescription Drugs Vis-à-vis Non-Prescription Drugs               II-14
       Table 4: Obesity Treatment Options and Corresponding Success
       Rate                                                             II-14

  5. Anti-Obesity Drugs- An Insight                                     II-15
      Introduction                                                      II-15
      Mechanism of Action                                               II-15
      Review of Available Drugs                                         II-16
       Phentermine                                                      II-16
       Sibutramine                                                      II-16
       Orlistat                                                         II-16
        Anti-obesity Drugs, Brands and Mechanism of Action              II-17
        Table 5: Global Anti-obesity Prescription Drugs Market
        (2006): Percentage Share Breakdown of Prescriptions by
        Physician Practices - Primary Care Physicians (PCP),
        Internal Medicine, Obsterics/Gynecology,
        Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and
        Others (includes corresponding Graph/Chart)                     II-17
      Review of Select Drugs Awaiting approval / Under Trials           II-17

  6. Recent Clinical Trials                                             II-20
      Genaera Initiates First Human Trial of Trodusquemine              II-20
      Neurogen Completes First Trial of NGD-4715                        II-20
      Alizyme Secures USFDA Approval for Cetilistat Trials              II-20
      GW Pharma to Start Human Trials of New Anti Obesity Drug          II-20
      Epix Completes Phase Ib Trial of PRX - 07034                      II-20
      7TM Pharma Starts Phase I/II Trial of TM30339                     II-21
      Arena Starts Phase III Clinical Trials of Lorcaserin              II-21
      Drug Induced Serotonin Could Promote Weight Loss                  II-21
      Takeda Initiates Phase II Clinical Trials of ALT-962              II-21
      Glenmark to Commence Phase I Trial of New Anti-Obesity Drug       II-21
      Amylin-Leptin Integrated Therapy to Treat Obesity                 II-21
      Vivus Completes Phase II Trial of Qnexa                           II-22
      VERNALIS Starts Phase I trial for Obesity                         II-22
      7TM Pharma Completes Phase I/ II Clinical Trials of TM30338       II-22
      Manhattan Pharmaceuticals Starts Phase I trial of Oleoyl estrone  II-22
      Arena Completes Phase2b Trials of APD356                          II-23
      Metabolic Accomplishes Phase 2b Trials of AOD9604                 II-23

  7. Product Approvals/Launches                                         II-24
      Sanofi-Aventis Receives Swiss Approval for Acomplia               II-24
      Zydus Cadila Introduces Slimona                                   II-24
      Torrent Introduces Rimoslim                                       II-24
      Gencor Introduces Slimaluma                                       II-24
      Orexigen Develops Excalia                                         II-24
      Scripps Research Institute Develops Vaccine for Obesity           II-25
      Sanofi-Aventis Receives Approval to Market Obesity Drug in EU     II-25
      Sanofi-Aventis Rolls Out Acomplia                                 II-25
      Sanofi Secures Approval for Acomplia in the UK                    II-25
      Novo Nordisk to Develop Anti-obesity Drug                         II-25
      Sanofi-Aventis Receives Approval to Market Acomplia in Mexico     II-26
      Ind-Swift Introduces Sibuslim-10                                  II-26
      Wellnx Launches NV                                                II-26
      Iron-Tek Introduces Appetite Suppressant                          II-26
      Yamanouchi and Keio University Discover Target Molecule for
       Developing Anti-obesity Drug                                     II-26

  8. Recent Industry Activity                                           II-27
      Pfizer Halts CP-945, 598 Development                              II-27
      Shionogi to Acquire Sciele Pharma                                 II-27
      Anthill Inks Agreement with Zafgen                                II-27
      EMEA Suspends Acomplia                                            II-27
      GlaxoSmithKline to Sell Alli as OTC Drug                          II-27
      Sanofi-Aventis to Market Acomplia in UK                           II-27
      Orexigen Receives 4th US Patent for Contrave                      II-28
      BELLUS Health to Acquire Innodia                                  II-28
      Ore Secures License to Develop Romazarit                          II-28
      GlaxoSmithKline Receives FDA Approval for Orlistat                II-28
      Pfizer Receives Approval for Slentrol                             II-28
      GlaxoSmithKline Secures Licensing Rights of Orlistat              II-28
      Pfizer Collaborates with Bristol-Myers Squibb                     II-29
      Takeda Collaborates with LG Life Sciences                         II-29
      Takeda to Acquire Paradigm                                        II-29
      Sanofi-Aventis Secures Reimbursement Status for Acomplia          II-30
      AstraZeneca Inks Agreement with Palatin Technologies              II-30
      Switzerland Includes Acomplia in Reimbursement List               II-30
      Allergan Pockets EndoArt                                          II-30
      Sanofi-Aventis Receives Approval for Acomplia in Brazil           II-31
      Biocon Inks MoU with Neopharma                                    II-31
      Aurigene Partners with Forest Laboratories                        II-31
      Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals      II-31
      Merck Terminates Collaboration with Nastech                       II-32
      Sanofi-Aventis to Receive Rights for Rimonabant                   II-32
      UMN Pharma Inks Agreement with Crucell and DSM Biologics          II-32
      7TM Pharma Pockets CareX SA                                       II-32
      BioLineRx Inks Licensing Agreement with Yissum                    II-33
      Aegis Inks Licensing Agreement with Albany Medical College        II-33
      Manhattan's Obesity Drug Approved for Human Trials                II-33
      Chugai Halts Development of Anti-Obesity Agent                    II-33
      HSG Acquires Polymann                                             II-33
      Orchid Pockets Bexel                                              II-34

  9. Focus on Select Players                                            II-35
      Abbott Laboratories (US)                                          II-35
      Alizyme Plc (UK)                                                  II-35
      Amylin Pharmaceuticals, Inc. (US)                                 II-35
      AstraZeneca Plc (UK)                                              II-36
      F. HOFFMANN-LA ROCHE LTD. (Switzerland)                           II-36
      GlaxoSmithKline Plc (UK)                                          II-36
      Sanofi-Aventis SA (France)                                        II-37
      SuperGen, Inc. (USA)                                              II-37
      Takeda Pharmaceutical Company Limited (Japan)                     II-38
      VIVUS, Inc. (US)                                                  II-38

  10. Global Market Perspective                                         II-39
      Table 6: World Recent Past, Current & Future Market Analysis
      for Anti-Obesity Drugs by Geographic Region - US, Europe and
      Rest of World Independently Analyzed with Annual Sales Figures
      in US$ million for Years 2005 through 2015 (includes
      corresponding Graph/Chart)                                        II-39

      Table 7: World 10-Year Perspective for Anti-Obesity Drugs by
      Geographic Region - Percentage Breakdown of Dollar Sales for
      US, Europe and Rest of World Markets for Years 2006, 2009 and
      2015 (includes corresponding Graph/Chart)                         II-40


III. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Market Overview                                                 III-1
         Table 8: Leading Product Segments in the US Weight Loss
         Market (2008E): Percent Share Breakdown of Revenues for
         Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods,
         Artificial Sweeteners, Weight Loss Centers, Medically
         Supervised Programs, Meal Replacements & Appetite
         Suppressants, Prescription Drugs, Low Calorie Diet Programs
         and Others (includes corresponding Graph/Chart)                III-1
         Obesity Catching Them Young                                    III-2
         New Drugs to Rule the Market                                   III-2
         37 States Experience Increase in Adult Obesity Rate            III-2
        Statistical Data                                                III-3
         Table 9: US Obesity Rate (2007): Prevalence Rate of Leading
         States                                                         III-3
         Table 10: US Obesity Prevalence Estimates and Forecasts 
          (2006-2020) (includes corresponding Graph/Chart)              III-4
         Table 11: US Overweight Prevalence (1998 & 2002): Breakdown
         of Adult population by Category - Overweight and Obese         III-4

         Table 12: US Obesity Prevalence (2005-2006): Breakdown of
         Population (%) by Sex and Age Group (includes corresponding
         Graph/Chart)                                                   III-4

         Table 13: US Anti-obesity Drugs Market (2006 & 2007):
         Number of Obese People Treated in Million                      III-5
        Reimbursement Scenario                                          III-5
        Regulatory Environment                                          III-5
         Insufficient Regulatory and Enforcement Laws                   III-5
        Obesity and Related Ailments: Burden on Societal and
         Economic Cost                                                  III-5
        Competition                                                     III-6
         Table 14: US Anti-obesity Drugs Market (2006 and 2007):
         Percentage Share Breakdown of Revenues by Brand - Meridia,
         Xenical and Others (includes corresponding Graph/Chart)        III-6
        Recent Clinical Trials                                          III-6
        Product Approval/Launches                                       III-8
        Strategic Corporate Developments                                III-9
        Review of Major Players                                         III-12
      B.Market Analytics                                                III-14
        Table 15: US Recent Past, Current & Future Analysis for
        Anti-Obesity Drugs Market Independently Analyzed with Annual
        Sales Figures in US$ million for Years 2005 through 2015
        (includes corresponding Graph/Chart)                            III-14

  2. Europe                                                             III-15
      A.Market Analysis                                                 III-15
        Market Overview                                                 III-15
        Lack of Reimbursement: Barrier to Market Growth                 III-15
        Statistical Data                                                III-16
         Table 16: Obesity Prevalence (2007) in Select European
         Union Countries: Obesity Rates by Gender (includes
         corresponding Graph/Chart)                                     III-16
         Table 17: Europe Obesity Prevalence (2007) by Gender and
          Age Category (in 000s) (includes corresponding Graph/
           Chart)                                                       III-16
        Overview of Novel Policies Adopted by Select European
         Countries to Prevent Obesity                                   III-17
      B.Market Analytics                                                III-18
        Table 18: European Recent Past, Current & Future Analysis
        for Anti-Obesity Drugs by Geographic Region/Country -
        France, Germany, Italy, UK and Rest of Europe Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2005 through 2015 (includes corresponding
        Graph/Chart)                                                    III-18

        Table 19: European 10-Year Perspective for Anti-Obesity
        Drugs by Geographic Region/Country - Percentage Breakdown of
        Dollar Sales for France, Germany, Italy, UK and Rest of
        Europe Markets for Years 2006, 2009 and 2015 (includes
        corresponding Graph/Chart)                                      III-19

  2a. France                                                            III-20
      A.Market Analysis                                                 III-20
        Market Overview                                                 III-20
         Changing Lifestyle Alter Health Profile                        III-20
        Product Approval/Launches                                       III-20
        Strategic Corporate Developments                                III-20
        Sanofi-Aventis SA - A Key Player                                III-21
      B.Market Analytics                                                III-22
        Table 20: French Recent Past, Current & Future Analysis for
        Anti-Obesity Drugs Market Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2005 through 2015
        (includes corresponding Graph/Chart)                            III-22

  2b. Germany                                                           III-23
      A.Market Analysis                                                 III-23
        Table 21: German Anti-obesity Drugs Market (2005 and 2006):
        Percentage Share Breakdown of Volume Sales by Leading Brands
        - Meridia and Xenical and Others                                III-23
      B.Market Analytics                                                III-23
        Table 22: German Recent Past, Current & Future Analysis for
        Anti-Obesity Drugs Market Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2005 through 2015
        (includes corresponding Graph/Chart)                            III-23

  2c. Italy                                                             III-24
       Market Analysis                                                  III-24
        Table 23: Italian Recent Past, Current & Future Analysis for
        Anti-Obesity Drugs Market Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2005 through 2015
        (includes corresponding Graph/Chart)                            III-24

  2d. The United Kingdom                                                III-25
      A.Market Analysis                                                 III-25
        Market Overview                                                 III-25
         Table 24: UK Childhood Prevalence (1995-2005): Percentage
         of Obese Children Aged 2-15 years (includes corresponding
         Graph/Chart)                                                   III-25
        Recent Clinical Trials                                          III-26
        Product Approval/Launches                                       III-26
        Strategic Corporate Developments                                III-27
        Review of Major Players                                         III-27
      B.Market Analytics                                                III-29
        Table 25: UK Recent Past, Current & Future Analysis for
        Anti-Obesity Drugs Market Independently Analyzed with Annual
        Sales Figures in US$ Million for Years 2005 through 2015
        (includes corresponding Graph/Chart)                            III-29

  2e. Rest of Europe                                                    III-30
      A.Market Analysis                                                 III-30
        Recent Clinical Trials                                          III-30
        Product Approval/Launches                                       III-30
        Strategic Corporate Developments                                III-31
        F. HOFFMANN-LA ROCHE LTD. - A Key Player                        III-31
      B.Market Analytics                                                III-32
        Table 26: Rest of Europe Recent Past, Current & Future
        Analysis for Anti-Obesity Drugs Market Independently
        Analyzed with Annual Sales Figures in US$ Million for Years
        2005 through 2015 (includes corresponding Graph/Chart)          III-32

  3. Rest of World                                                      III-33
      A.Market Analysis                                                 III-33
        Brief Review of Select Regions                                  III-33
         Canada                                                         III-33
          Table 27: Canadian Obesity Prevalence (1979 & 2004):
          Obesity Rate by Age Group (includes corresponding
          Graph/Chart)                                                  III-33

          Table 28: Canadian Adult Overweight and Obesity Prevalence
          (2004): Breakdown of Population (in 000s) by Sex              III-33
         Asia-Pacific                                                   III-34
          Australia                                                     III-34
           Table 29: Prevalence Rate (%) of overweight/obese
            Students in Australia (includes corresponding Graph/
             Chart)                                                     III-34
          China                                                         III-35
          India                                                         III-35
           Drugs Under Development by Indian Companies                  III-35
          Japan                                                         III-35
           Takeda Pharmaceutical Company Limited - A Key Player         III-35
          Korea                                                         III-36
           Use of Diet Pills Lack Proper Monitoring                     III-36
          New Zealand                                                   III-36
        Recent Clinical Trials                                          III-36
        Product Approval/Launches                                       III-37
        Strategic Corporate Developments                                III-38
      B.Market Analytics                                                III-41
        Table 30: Rest of World Recent Past, Current & Future
        Analysis for Anti-Obesity Drugs Market Independently
        Analyzed with Annual Sales Figures in US$ Million for Years
        2005 through 2015 (includes corresponding Graph/Chart)          III-41


 IV. COMPETITIVE LANDSCAPE